Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC

Kristian Steen Frederiksen, Mercè Boada, Lutz Frölich, M. Kramberger, Nikolaos Scarmeas, Everard Vijverberg, Pieter Jelle Visser, Gunhild Waldemar, Eric Westman, Henrik Zetterberg, Sebastiaan Engelborghs, Frank Jessen

原始摘要（英文原文）· Original abstract

Frederiksen, Kristian Steen; Boada, Mercè; Frölich, Lutz; Kramberger, Milica; Scarmeas, Nikolaos; Vijverberg, Everard; Visser, Pieter Jelle; Waldemar, Gunhild; Westman, Eric; Zetterberg, Henrik; Engelborghs, Sebastiaan; Jessen, Frank

读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC

AI 追问PRO

讨论区

相关论文 · Related